ResearchDx Inc (ResearchDx), a premier Contract Diagnostics Organization (CDO) offering complete in vitro diagnostic (IVD) services and INOVIQ Limited (INOVIQ)
ResearchDx Inc (ResearchDx), a premier Contract Diagnostics Organization (CDO) offering complete in vitro diagnostic (IVD) services and INOVIQ Limited (INOVIQ), a developer of next-generation exosome solutions and precision diagnostics, today announced a license and supply agreement for INOVIQ’s EXO-NET® exosome capture technology to enable provision of exosome isolation, biomarker discovery and diagnostics development services in the USA. This agreement will enable the companies to deliver EXO-NET enabled High-Throughput (HT) exosome isolation, biomarker discovery and diagnostics development services to customers in the USA.
This new agreement combines the expertise of ResearchDx in the development and validation of IVD diagnostics, with INOVIQ’s disruptive EXO-NET technology, exosome capture tools and exosome- based diagnostics expertise.
ResearchDx and INOVIQ are excited to leverage their combined exosome and IVD diagnostics development expertise to advance exosome-based diagnostics development for companion diagnostics to deliver the right medicines to the right patients to improve therapeutic outcomes.
Dr Mat Moore, ResearchDx Principal & Co-Founder, said: “We look forward to offering EXO-NET enabled EV isolation, biomarker discovery and diagnostic development services in our Development, GLP, and CLIA accredited laboratories to US customers. EXO-NET is a powerful exosome isolation platform that has the potential to enable earlier disease detection, and the more accurate monitoring of disease progression and response to therapy.”